Growth leadership Leadership change with the appointment of a new CEO Rob Bryant as of June 2024 signals a potential organizational shift and renewed strategic emphasis, suggesting a timely window for engaging in high-level discussions on go-to-market plans, channel partnerships, and product roadmap alignment.

Strategic partnerships Past and ongoing collaborations with academic and veterinary institutions (West Virginia University and Mandai Wildlife Group) indicate a receptiveness to co-development and contract research. Sales opportunities exist in joint development projects, pilot programs, and expanded PET/CT or veterinary imaging ventures.

Product expansion Matters of product line focus on compact CT solutions (MiniCAT, xCAT ENT mobile intraoperative CT) and XoranConnect for imaging workflow. Upsell and cross-sell opportunities include upgraded imaging capabilities, mobile CT deployments in clinics or hospitals, and value-added software subscriptions.

Operational scale Revenue range ($10–$25M) with a relatively small team (11–50 employees) points to a lean organization likely seeking scalable partnerships, channel distribution, and cost-effective sales models to accelerate growth and market penetration in niche medical imaging markets.

Healthcare focus Emphasis on low-dose, patient-friendly CT imaging and veterinary 3D CT deployments aligns with opportunities to target hospitals, clinics, veterinary centers, and academic medical centers seeking compact, cost-efficient imaging solutions and workflow integrations.